Sara Mazzuoccolo serves as the Licensing Director at ITALFARMACO S.P.A., where she plays a pivotal role in driving the company’s growth strategy through strategic partnerships and licensing initiatives. With a robust background in global marketing and business development, Sara excels in identifying and evaluating both...
Sara Mazzuoccolo serves as the Licensing Director at ITALFARMACO S.P.A., where she plays a pivotal role in driving the company’s growth strategy through strategic partnerships and licensing initiatives. With a robust background in global marketing and business development, Sara excels in identifying and evaluating both in-licensing and out-licensing opportunities across various stages of product development, including R&D and complex generics. Her expertise in negotiating third-party license agreements and distribution contracts has been instrumental in securing advantageous terms that align with ITALFARMACO’s objectives.
Sara's current projects include spearheading the acquisition of innovative medical devices and pharmaceutical products that complement the company's existing portfolio. She is adept at navigating the complexities of deal structuring, ensuring that all transactions are executed efficiently and in compliance with regulatory standards. Her strategic approach to partnership management has fostered strong relationships with both national and international stakeholders, enhancing ITALFARMACO’s market presence and operational efficiency.
In addition to her licensing responsibilities, Sara is actively involved in sales strategy development and sales support, working closely with cross-functional teams to optimize product launches and streamline production logistics. Her ability to balance budgeting with strategic foresight allows her to contribute significantly to the company’s bottom line while maintaining a focus on long-term growth. With a commitment to excellence and a passion for innovation, Sara Mazzuoccolo continues to be a driving force behind ITALFARMACO S.P.A.'s success in the competitive pharmaceutical landscape.